{Reference Type}: Journal Article
{Title}: Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation.
{Author}: Zhao C;Zhang R;Yang H;Gao Y;Zou Y;Zhang X;
{Journal}: Biochem Pharmacol
{Volume}: 226
{Issue}: 0
{Year}: 2024 Aug 20
{Factor}: 6.1
{DOI}: 10.1016/j.bcp.2024.116378
{Abstract}: Lung cancer is the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all lung cancers and having a poor treatment and prognosis. Conventional clinical chemotherapy and immunotherapy are challenged by systemic toxicity and drug resistance, so researchers are increasingly focusing on antibody-drug conjugate (ADC), an innovative concept combining chemotherapy and targeted therapy, in which a drug selectively binds to antigens on the surface of a tumor cell via antibodies, which internalize the ADC, and then transfers the ADC to the lysosome via the endosomes to degrade the drug and kill the tumor cell. Despite the promising nature of ADCs, no ADC product for any indication including NSCLC has been approved for marketing by the FDA to date. In this review, we summarize the main advantages of ADCs and discuss in depth the design of the most desirable ADCs for NSCLC therapy. In addition to preclinical studies, we focus on the current state of clinical research on ADCs as interventions for the treatment of NSCLC by summarizing real-time clinical trial data from ClinicalTrials.gov, and reasonably speculate on the direction of the design of future generations of ADCs.